case_images: PMC9803626_01
case_images: Brain MRI slices (A, cerebrum; B, cerebellum) acquired in the initial assessment did not show any abnormal findings
case_images: AOJNMB-11-93-g001.jpg
case_images: PMC9803626_01_AOJNMB-11-93-g001.jpg
case_images: F1
case_images: No abnormality was noted on MRI of the brain (Figure 1) or laboratory tests.
case_images: The entire cerebellum showed severe atrophy on Brain MRI (A), and much lower uptake than that in the cerebral cortex on perfusion SPECT and corresponding fused SPECT/MRI (B-E)
case_images: AOJNMB-11-93-g002.jpg
case_images: PMC9803626_01_AOJNMB-11-93-g002.jpg
case_images: F2
case_images: MRI and much lower uptake than that in the cerebral cortex on SPECT (Figure 2). Myoclonus newly appeared during hospitalization.
case_images: Fat suppressed T2-weighted MRI visualized a small mass behind the inferior vena cava (A). Its uptake was equal to the liver on I-123 MIBG scintigraphy (B-C)
case_images: AOJNMB-11-93-g003.jpg
case_images: PMC9803626_01_AOJNMB-11-93-g003.jpg
case_images: F3
case_images: Fat suppressed T2-weighted MRI visualized a small mass behind the inferior vena cava (Figure 3, A). We further performed I-123 metaiodobenzyl-guanidine (MIBG) scintigraphy and found that the MIBG uptake in the tumor was comparable to that in the liver, although the small size of the lesion made it difficult to evaluate the true uptake in the tumor (Figure 3, B-C).